Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Ocuphire's Nightblindness Candidate Meets Primary Endpoint In Phase 3 Study

Ocuphire Pharma Inc (NASDAQ:OCUP) has announced topline results from the LYNX-1 Phase 3 trial investigating Nyxol for night (or dim light) vision disturbances (NVD).

  • The FDA-agreed primary endpoint was met, with a statistically significant greater percentage of Nyxol-treated subjects having gained 15 or more letters of mesopic low contrast distance visual acuity (mLCVA) at Day 8, compared to placebo (13% vs. 3%).
  • Related: Ocuphire Pharma's Shares Fall Despite Positive Data From Registrational Phase 3 Trial Of Nyxol.
  • The effect of Nyxol increased at Day 15, with 21% of subjects gaining 15 or more letters of mLCVA compared to 3% placebo.
  • Nyxol significantly increased the percentage of subjects gaining 10 or more letters of mLCVA at both Day 8 with 41% vs. 22% placebo and at Day 15 with 44% vs. 23%.
  • Nyxol showed a favorable safety and tolerability profile. There were no serious adverse events, and adverse events in Nyxol-treated subjects were predominantly mild.
  • Price Action: OCUP shares are down 8.25% at $1.95 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.